礼来收购Ventyx Biosciences获美国联邦贸易委员会批准

Core Viewpoint - The U.S. Federal Trade Commission has issued an early termination notice regarding Eli Lilly's acquisition of Ventyx Biosciences, indicating regulatory approval for the transaction [1] Group 1: Transaction Details - Eli Lilly plans to acquire all outstanding shares of Ventyx Biosciences for $14 per share, valuing the total equity of the transaction at approximately $1.2 billion [1] - The completion of the transaction is expected in the first half of 2026 [1]